长期释放的氨酸胺微球使用电喷技术用于非传染性紫外炎治疗
Jiayu Xie1,2,3, Ke Li1,2,3, Lusi Chen1,2,3
1School of Pharmacy, Jiangxi University of Chinese Medicine, Nanchang, China.
Pharmaceutical development and technology
|February 3, 2025
概括
装有素乙化物 (FA@MS) 的可生物降解微球为非传染性脑膜炎 (NIU) 治疗提供持续释放. 这种新配方显示出对长期眼内药物输送具有有利的生物安全性的承诺.
科学领域:
- 眼科医生 眼科 眼科
- 材料科学 材料科学 材料科学
- 药物运输 药物运输 药物运输
背景情况:
- 非传染性脑膜炎 (NIU) 的治疗往往需要重复的玻璃内注射.
- 目前的不可生物降解的植入物会导致低血压和二次损伤等不良影响.
- 对NIU而言,需要更安全,长效的静脉内药物输送系统.
研究的目的:
- 开发和表征可生物降解的基于聚糖乳糖酸 (PLGA) 的微球 (FA@MS) 用于持续的内输送氨酸 (FA).
- 评估FA@MS在非传染性脑膜炎 (NIU) 治疗中的*体外*和*体内*性能.
主要方法:
- 优化的电喷技术被用于准备具有特定电压和接收距离参数的FA@MS.
- 微球的特征包括颗粒大小,封装效率和药物含量分析.
- 在子NIU模型中进行了*in vitro*药物释放研究和*in vivo*疗效和安全性评估.
主要成果:
- 在FA@MS中,平均颗粒大小为2.25μm,封装效率高 (94.85%) 和药物含量高 (9.48%) 的药物被成功制备.
- 实验室研究显示,FA持续释放30天,符合韦布尔模型.
- *体内*研究表明,药物在玻璃体中持续释放至少28天,有效降低NIU炎症和正常的眼内压力,这表明生物安全性有利.
结论:
- 通过电子喷雾技术制备的可生物降解FA@MS为非传染性脑膜炎 (NIU) 治疗提供了有前途的长期作用的视觉内制剂.
- FA@MS配方提供持续的药物释放和有利的生物安全性,与频繁注射或非生物降解植入物相比,可能改善患者的服药性.
相关概念视频
Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Modified-Release Drug Delivery Systems: Site-Targeted
167
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
167
Ophthalmic Drug Delivery Systems
285
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
285


